Theonie Anastassiadis
Gründer bei Flagship Labs 89, Inc.
Profil
Ms. Theonie Anastassiadis is a Chief Innovation Officer at Alltrna, a President at Prologue Medicines, Inc. and a Principal at Flagship Pioneering.
She received her undergraduate degree from Haverford College.
Aktive Positionen von Theonie Anastassiadis
Unternehmen | Position | Beginn |
---|---|---|
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Private-Equity-Analyst | - |
Alltrna
Alltrna BiotechnologyHealth Technology Alltrna is a biotech company that uses AI/ML tools to learn the language of tRNA and develop programmable molecules with therapeutic potential. Alltrna was founded in 2018 by Flagship Pioneering and is based in Cambridge, MA. The company aims to correct diseases by advancing a single tRNA medicine to treat a wide range of diseases with the same underlying genetic mutation. The company's CEOs are Michelle C. Werner and Lovisa Afzelius. | Gründer | - |
Flagship Labs 89, Inc. | Gründer | - |
Ausbildung von Theonie Anastassiadis
Haverford College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Alltrna
Alltrna BiotechnologyHealth Technology Alltrna is a biotech company that uses AI/ML tools to learn the language of tRNA and develop programmable molecules with therapeutic potential. Alltrna was founded in 2018 by Flagship Pioneering and is based in Cambridge, MA. The company aims to correct diseases by advancing a single tRNA medicine to treat a wide range of diseases with the same underlying genetic mutation. The company's CEOs are Michelle C. Werner and Lovisa Afzelius. | Health Technology |
Flagship Labs 89, Inc. | Health Technology |